Accessibility Menu
Kardigan logo

Kardigan(NASDAQ) KARD

Market Cap$1.89BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2026)-9%
5 YearN/A
1 YearN/A
1 Month-3%
$20.29
+1.35%
+0.27Today
After hours$20.28-$0.01 (-0.05%)
Kardigan last closing stock price
MetricPriceDate
Last closeUSD 20.162026-08-31
Kardigan stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-2.33%USD 20.642026-08-24
1 month-3.17%USD 20.822026-07-31
Since inception-9%USD 22.002026-06-18

Kardigan Financials at a Glance

Market Cap

$1.89BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$247.77

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-1.73 (Low)

Price

$20.29

Volume

184,888.245

Open

$20.02

Previous Close

$20.16

Daily Range

$20.00 - $20.72

52-Week Range

$16.00 - $27.00

Estimated Earnings Date

Sep 2, 2026

KARD News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Kardigan

Kardigan, Inc. is a clinical-stage precision therapeutics company focused on developing innovative medicines for cardiovascular diseases lacking approved treatments. Utilizing its “Cardiac Intelligence” platform, the company integrates artificial intelligence and real-world patient data to enhance research and treatment outcomes.

Products and Services
  • Development of precision therapeutics targeting cardiovascular diseases
  • Integration of AI and analytics through the Cardiac Intelligence platform
  • Research programs aimed at improving patient outcomes
Growth Outlook
  • Founded in August 2023, Kardigan is positioned for rapid growth in the biotech sector
  • Strong cash reserves of $384 million as of June 2026 support ongoing research
  • Market demand for innovative cardiovascular treatments continues to rise
Financial Highlights
  • Recent quarterly net income of -$116 million reflects ongoing investment in R&D
  • Cash and short-term investments total $597 million, providing financial stability
  • Current ratio of 8.72 indicates strong liquidity and ability to meet short-term obligations
AI Generated • Aug 19, 2026

Industry

Pharmaceuticals

Employees

241

CEO

Tassos Gianakakos, MBA

Headquarters

Princeton, NJ 08540, US

KARD Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-109.44%

Return on Capital

N/A

Return on Assets

-23.87%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.89BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

93.50M

Volume

184.89K

Avg. Volume

447.08K

Financials (TTM)

Gross Profit

-$2.19M

Operating Income

-$133.94M

EBITDA

-$129.63M

Operating Cash Flow

-$107.33M

Capital Expenditure

-$3.56M

Free Cash Flow

-$110.88M

Cash & ST Invst.

$597.60M

Total Debt

$13.35M

Kardigan Performance Analysis

Kardigan annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Kardigan sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12026-03-31N/A
Q22026-06-30N/A
Kardigan annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20242024-12-31USD -0.99N/A
20252025-12-31USD -2.15116.5%
Kardigan sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12026-03-31N/A
Q22026-06-30-37.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$2.19M

N/A

Gross Margin

0.00%

N/A

Market Cap

$1.89BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$7.82M

N/A

Employees

241

N/A

Net Income

-$116.24M

N/A

EBITDA

-$73.04M

N/A

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$597.60M

N/A

Total Debt

$13.35M

N/A

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$9.60M

N/A

Short Term Debt

$3.75M

N/A

Return on Assets

-23.87%

N/A

Return on Invested Capital

-20.55%

N/A

Free Cash Flow

-$51.48M

N/A

Operating Cash Flow

-$50.55M

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,684.24-0.00%
^DJIDJI
$53,254.61-0.01%
^IXICNASDAQ
$26,319.55-0.00%
BTCBitcoin
$78,890.00-0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.27-0.20%
NVDANvidia
$220.78+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.97+0.11%
CNHCNH Industrial
$11.83+0.01%

Questions About KARD

What is the current price of Kardigan?

Kardigan is trading at $20.16 per share.

What is the 52-week range for Kardigan?

Over the past 52 weeks, Kardigan has traded between $16.00 and $27.00.

How much debt does Kardigan have?

As of the most recent reporting period, Kardigan reported total debt of $13.35M.

How much cash does Kardigan have on hand?

Kardigan reported $384.01M in cash and cash equivalents in its most recent financial results.

What is Kardigan’s dividend yield?

Kardigan does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.